Bristol Myers Squibb (NYSE:BMY) Upgraded at UBS Group

UBS Group upgraded shares of Bristol Myers Squibb (NYSE:BMY) from a neutral rating to a buy rating in a research report report published on Wednesday morning, MarketBeat Ratings reports. They currently have $65.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $46.00.

A number of other research analysts have also recently issued reports on the stock. Morgan Stanley restated an “underweight” rating and set a $37.00 price objective (up previously from $36.00) on shares of Bristol Myers Squibb in a report on Friday, December 12th. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 3rd. Guggenheim reiterated a “buy” rating on shares of Bristol Myers Squibb in a report on Tuesday, December 23rd. Finally, Scotiabank restated a “sector perform” rating and issued a $53.00 price target (up from $45.00) on shares of Bristol Myers Squibb in a report on Thursday, December 4th. Six research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $56.62.

Bristol Myers Squibb Stock Up 0.0%

NYSE:BMY opened at $55.92 on Wednesday. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $63.33. The stock’s fifty day simple moving average is $50.93 and its 200-day simple moving average is $47.80. The firm has a market capitalization of $113.84 billion, a P/E ratio of 18.89, a P/E/G ratio of 9.29 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. The firm had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company’s quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities research analysts expect that Bristol Myers Squibb will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.5%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is 85.14%.

Hedge Funds Weigh In On Bristol Myers Squibb

Several hedge funds have recently made changes to their positions in the business. Gateway Investment Advisers LLC increased its holdings in shares of Bristol Myers Squibb by 10.0% during the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after acquiring an additional 10,284 shares during the last quarter. Commonwealth Retirement Investments LLC increased its holdings in shares of Bristol Myers Squibb by 24.6% in the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock valued at $2,740,000 after purchasing an additional 11,690 shares during the last quarter. CWA Asset Management Group LLC raised its position in shares of Bristol Myers Squibb by 25.9% in the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after purchasing an additional 30,909 shares during the period. Norges Bank acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth about $1,554,154,000. Finally, Wealth Quarterback LLC boosted its holdings in shares of Bristol Myers Squibb by 42.6% during the 2nd quarter. Wealth Quarterback LLC now owns 25,443 shares of the biopharmaceutical company’s stock worth $1,178,000 after buying an additional 7,603 shares during the period. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: UBS upgraded BMY, citing improved fundamentals and/or valuation support from recent earnings and guidance — a boost for investor confidence and likely a contributor to buying interest. Bristol Myers Squibb (NYSE:BMY) Stock Rating Upgraded by UBS Group
• Positive Sentiment: Piper Sandler reiterated a buy rating for BMY, reinforcing sell‑side support and reducing downside risk from analyst sentiment. Piper Sandler Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY)
• Positive Sentiment: BioNTech and Bristol Myers Squibb expanded a pancreatic cancer program with a new Phase II trial — clinical progress in a high‑need oncology indication improves long‑term upside potential if data are positive. BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial
• Positive Sentiment: BMY added a new immunotherapy combo in small‑cell lung cancer, broadening its oncology pipeline and potential label-expansion or combination opportunities. Pipeline depth tends to support premium multiples in pharma names. Bristol Myers Squibb Adds New Immunotherapy Combo Bet in Small Cell Lung Cancer
• Neutral Sentiment: Analyst/industry pieces (Argus, Yahoo valuation reviews, and a Zacks recap) note BMY’s recent share gains and evolving profitability story but raise valuation questions as shares have recovered — these provide context but no immediate directional trigger. Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves
• Neutral Sentiment: CNBC preview of the JPMorgan Healthcare Conference highlights that the event could be a catalyst (pipeline updates, commercialization and M&A talk) for BMY, but outcomes depend on what management and peers announce. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Headline pieces summarizing recent developments (Yahoo/TipRanks recaps) provide useful investor reading but are largely descriptive rather than delivering a single market-moving event. How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.